Prevalence of Preeclampsia in Brazil: An Integrative Review

Abstract

Objective To review literature and estimate the occurrence of preeclampsia and its complications in Brazil.

Methods We performed an integrative review of the literature, and included observational studies published until August 2021 on the SciELO and PubMed databases that evaluated preeclampsia among pregnant women in Brazil. Other variables of interests were maternal death, neonatal death, hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome, and eclampsia. Three independent reviewers evaluated all retrieved studies and selected those that met inclusion criteria. A metanalysis of the prevalence of preeclampsia and eclampsia was also performed, to estimate a pooled frequency of those conditions among the studies included.

Results We retrieved 304 studies after the initial search; of those, 10 were included in the final analysis, with a total of 52,986 women considered. The pooled prevalence of preeclampsia was of 6.7%, with a total of 2,988 cases reported. The frequency of eclampsia ranged from 1.7% to 6.2%, while the occurrence of HELLP syndrome was underreported. Prematurity associated to hypertensive disorders ranged from 0.5% to 1.72%.

Conclusion The frequency of preeclampsia was similar to that reported in other international studies, and it is increasing in Brazil, probably due to the adoption of new diagnostic criteria. The development of a national surveillance network would be essential to understand the problem of hypertensive disorders of pregnancy in Brazil.

Resumo

Objetivo Revisar a literatura e estimar a ocorrência de pré-eclâmpsia e suas complicações no Brasil.

Métodos Foi realizada uma revisão integrativa da literatura, com a inclusão de estudos observacionais publicados até agosto de 2021, nas bases de dados PubMed e SciELO, que avaliavam pré-eclâmpsia em mulheres brasileiras. Outras variáveis de interesse foram morte materna, morte neonatal, síndrome de hemólise, enzimas hepáticas elevadas e plaquetopenia (hemolysis, elevated liver enzymes, and low platelet count, HELLP, em inglês) e eclâmpsia. Três revisores independentes avaliaram os estudos identificados e selecionaram aqueles que preenchiam os critérios de inclusão. Foi realizada uma meta-análise da prevalência de pré-eclâmpsia e eclâmpsia, para estimar sua frequência acumulada com relação aos estudos incluídos.

Resultados Foram identificados 304 estudos, 10 dos quais foram incluídos na análise final, num total de 52.986 mulheres. A frequência acumulada de pré-eclâmpsia foi de 6,7%, com um total de 2.988 casos. A frequência de eclâmpsia variou de 1,7% a 6,2%, ao passo que a ocorrência de síndrome de HELLP foi pouco relatada. A prematuridade associada a hipertensão foi de 0,5% a 1,7%.

Conclusão A frequência de pré-eclâmpsia foi similar à de estudos internacionais; no entanto, ao longo dos últimos anos, ela vem aumentando no Brasil, possivelmente como reflexo da adoção de novos critérios diagnósticos. A criação de uma rede nacional de vigilância seria fundamental para entender o problema da hipertensão na gestação no país.

Keywords

preeclampsia - epidemiology - Brazil

Palavras-chave

pré-eclâmpsia - epidemiologia - Brasil

Publication History

Received: 12 September 2021

Accepted: 10 December 2021

Article published online:
09 February 2022

• References

• 1 Lotufo FA, Parpinelli MA, Osis MJ, Surita FG, Costa ML, Cecatti JG. Situational analysis of facilitators and barriers to availability and utilization of magnesium sulfate for eclampsia and severe preeclampsia in the public health system in Brazil. BMC Pregnancy Childbirth 2016; 16 (01) 254 DOI: 10.1186/s12884-016-1055-0.
• 2 Giordano JC, Parpinelli MA, Cecatti JG, Haddad SM, Costa ML, Surita FG. et al. The burden of eclampsia: results from a multicenter study on surveillance of severe maternal morbidity in Brazil. PLoS One 2014; 9 (05) e97401 DOI: 10.1371/journal.pone.0097401.
• 3 Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33 (03) 130-137 DOI: 10.1053/j.semperi.2009.02.010.
• 4 França EB, Lansky S, Rego MAS, Malta DC, França JS, Teixeira R. et al. Leading causes of child mortality in Brazil, in 1990 and 2015: estimates from the Global Burden of Disease study. Rev Bras Epidemiol 2017; 20 (20, Suppl 01) 46-60 DOI: 10.1590/1980-5497201700050005.
• 5 Guida JP, Costa ML, Parpinelli MA, Pacagnella RC, Ferreira EC, Mayrink J. et al. Brazilian Cohort on Severe Maternal Morbidity (COMMAG) study group and the WHO Maternal Morbidity Working Group (MMWG). The impact of hypertension, hemorrhage, and other maternal morbidities on functioning in the postpartum period as assessed by the WHODAS 2.0 36-item tool. Int J Gynaecol Obstet 2018; 141 (Suppl. 01) 55-60 DOI: 10.1002/ijgo.12467.
• 6 Firoz T, McCaw-Binns A, Filippi V, Magee LA, Costa ML, Cecatti JG. et al. members of the WHO Maternal Morbidity Working Group (MMWG). A framework for healthcare interventions to address maternal morbidity. Int J Gynaecol Obstet 2018; 141 (Suppl. 01) 61-68 DOI: 10.1002/ijgo.12469.
• 7 Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W. et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens 2014; 4 (02) 97-104 DOI: 10.1016/j.preghy.2014.02.001.
• 8 von Dadelszen P, Magee LA. Pre-eclampsia: an update. Curr Hypertens Rep 2014; 16 (08) 454 DOI: 10.1007/s11906-014-0454-8.
• 9 Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health 2013; 67 (11) 974-978 DOI: 10.1136/jech-2013-203104.
• 10 Mayrink J, Souza RT, Feitosa FE, Roch a Filho EA, Leite DF, Vettorazzi J. et al. Preterm SAMBA study group. Incidence and risk factors for Preeclampsia in a cohort of healthy nulliparous pregnant women: a nested case-control study. Sci Rep 2019; 9 (01) 9517 DOI: 10.1038/s41598-019-46011-3.
• 11 Gaio DS, Schmidt MI, Duncan BB, Nucci LB, Matos MC, Branchtein L. Hypertensive disorders in pregnancy: frequency and associated factors in a cohort of Brazilian women. Hypertens Pregnancy 2001; 20 (03) 269-281 DOI: 10.1081/PRG-100107829.
• 12 Gonçalves R, Fernandes RA, Sobral DH. [Prevalence of specific hypertensive disease of pregnancy in a public hospital of the city of São Paulo]. Rev Bras Enferm 2005; 58 (01) 61-64 DOI: 10.1590/s0034-71672005000100011.
• 13 Dantas EM, Pereira FV, Queiroz JW, Dantas DL, Monteiro GR, Duggal P. et al. Preeclampsia is associated with increased maternal body weight in a northeastern Brazilian population. BMC Pregnancy Childbirth 2013; 13: 159 DOI: 10.1186/1471-2393-13-159.
• 14 Wendland EM, Duncan BB, Belizán JM, Vigo A, Schmidt MI. Gestational diabetes and pre-eclampsia: common antecedents?. Arq Bras Endocrinol Metabol 2008; 52 (06) 975-984 DOI: 10.1590/s0004-27302008000600008.
• 15 Reichelt AJ, Weinert LS, Mastella LS, Gnielka V, Campos MA, Hirakata VN. et al. Clinical characteristics of women with gestational diabetes - comparison of two cohorts enrolled 20 years apart in southern Brazil. Sao Paulo Med J 2017; 135 (04) 376-382 DOI: 10.1590/1516-3180.2016.0332190317.
• 16 Sanchez MP, Guida JP, Simões M, Marangoni-Junior M, Cralcev C, Santos JC. et al. Can pre-eclampsia explain higher cesarean rates in the different groups of Robson's classification?. Int J Gynaecol Obstet 2021; 152 (03) 339-344 DOI: 10.1002/ijgo.13370.
• 17 Trindade CR, Torloni MR, Mattar R, Sun SY. Good performance of bioimpedance in early pregnancy to predict preeclampsia. Pregnancy Hypertens 2021; 26: 24-30 DOI: 10.1016/j.preghy.2021.08.115.
• 18 de Lima MC, Santos IDS, Crivellenti LC, Sartorelli DS. A better quality of maternal dietary fat reduces the chance of large-for-gestational-age infants: A prospective cohort study. Nutrition 2021; ;91-92: 111367 DOI: 10.1016/j.nut.2021.111367.
• 19 Ramos Filho FL, Antunes CMF. Hypertensive disorders: prevalence, perinatal outcomes and cesarean section rates in pregnant women hospitalized for delivery. Rev Bras Ginecol Obstet 2020; 42 (11) 690-696 DOI: 10.1055/s-0040-1714134.
• 20 Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J. et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health 2014; 2 (06) e323-e333 DOI: 10.1016/S2214-109X(14)70227-X.
• 21 Guida JP, Parpinelli MA, Surita FG, Costa ML. The impact of proteinuria on maternal and perinatal outcomes among women with pre-eclampsia. Int J Gynaecol Obstet 2018; 143 (01) 101-107 DOI: 10.1002/ijgo.12487.
• 22 Duffy J, Cairns AE, Richards-Doran D, van 't Hooft J, Gale C, Brown M. et al. International Collaboration to Harmonise Outcomes for Pre-eclampsia (iHOPE). A core outcome set for pre-eclampsia research: an international consensus development study. BJOG 2020; 127 (12) 1516-1526 DOI: 10.1111/1471-0528.16319.
• 23 Webster LM, Myers JE, Nelson-Piercy C, Harding K, Cruickshank JK, Watt-Coote I. et al. Labetalol versus nifedipine as antihypertensive treatment for chronic hypertension in pregnancy: a randomized controlled trial. Hypertension 2017; 70 (05) 915-922 DOI: 10.1161/HYPERTENSIONAHA.117.09972.